Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

109.30
+0.95000.88%
Pre-market: 110.821.52+1.39%07:14 EDT
Volume:1.04M
Turnover:112.60M
Market Cap:9.09B
PE:-34.03
High:110.04
Open:106.52
Low:104.19
Close:108.35
52wk High:130.05
52wk Low:55.26
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.09
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.02
PE(LYR):-29.62

Loading ...

Top Midday Gainers

MT Newswires Live
·
Jun 26

Kymera Therapeutics Price Target Maintained with a $134.00/share by BTIG

Dow Jones
·
Jun 26

Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment

TIPRANKS
·
Jun 25

Kymera Therapeutics Shares Jump After Accelerating Kt-621 Trial Timeline

Dow Jones
·
Jun 25

Kymera Therapeutics rises 18.6%

TIPRANKS
·
Jun 25

Analysts Are Bullish on Top Healthcare Stocks: Alpha Teknova (TKNO), Kymera Therapeutics (KYMR)

TIPRANKS
·
Jun 25

Shares of Kymera Therapeutics up 10.2% Premarket After Co Completes Enrollment for Mid-stage Eczema Trial

THOMSON REUTERS
·
Jun 25

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

Kymera Therapeutics Advances KT-621 Development With Phase 2b Enrollment Completion

MT Newswires Live
·
Jun 25

Kymera Therapeutics - Phase 3 Trials in Atopic Dermatitis Expected to Initiate by Mid-2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics - Kt-621 Breadth Phase 2B Asthma Trial Data Expected in Late 2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Completes Enrollment in the Phase 2B Broaden2 Trial of Kt-621 in Atopic Dermatitis with Topline Data by Year-end 2026

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Shareholders Elect Booth, Mainolfi, Maraganore, Ridloff as Class III Directors

Reuters
·
Jun 25

Kymera Therapeutics Names Felix Baker Board Chairman, Replacing Bruce Booth

Reuters
·
Jun 25

Kymera Therapeutics Appoints Felix J. Baker, Ph.d., as Chairman of the Board of Directors

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Chief Business Officer Noah Goodman reports sale of 2,500 shares worth $247,500

Reuters
·
Jun 23

Kymera Therapeutics (KYMR) Receives a Buy from Barclays

TIPRANKS
·
Jun 22

Kymera Therapeutics participates in a conference call with JPMorgan

TIPRANKS
·
Jun 18

Why Kymera Therapeutics (KYMR) Is Up 16.6% After Positive KT-621 Phase 1 Japanese Data

Simply Wall St.
·
Jun 16

Kymera reports Phase 1 data in healthy Japanese adults for KT-621 oral STAT6 degrader

Reuters
·
Jun 12